These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 34590451)

  • 1. Current treatment challenges in the COVID-19 pandemic.
    Patrucco F; Gavelli F; Fagoonee S; Solidoro P; Undas A; Pellicano R
    Pol Arch Intern Med; 2021 Sep; 131(9):854-861. PubMed ID: 34590451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.
    Ahn JY; Sohn Y; Lee SH; Cho Y; Hyun JH; Baek YJ; Jeong SJ; Kim JH; Ku NS; Yeom JS; Roh J; Ahn MY; Chin BS; Kim YS; Lee H; Yong D; Kim HO; Kim S; Choi JY
    J Korean Med Sci; 2020 Apr; 35(14):e149. PubMed ID: 32281317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
    Lindholm PF; Ramsey G; Kwaan HC
    Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
    Wiersinga WJ; Rhodes A; Cheng AC; Peacock SJ; Prescott HC
    JAMA; 2020 Aug; 324(8):782-793. PubMed ID: 32648899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.
    Bormann M; van de Sand L; Witzke O; Krawczyk A
    Klin Monbl Augenheilkd; 2021 May; 238(5):569-578. PubMed ID: 34020485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
    De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
    Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Therapy for COVID-19: Categories, Pros, and Cons.
    Zare Marzouni H; Rahbar M; Seddighi N; Nabizadeh M; Meidaninikjeh S; Sabouni N
    Viral Immunol; 2022 Oct; 35(8):517-528. PubMed ID: 36201297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study.
    Procopio G; Cancelliere A; Trecarichi EM; Mazzitelli M; Arrighi E; Perri G; Serapide F; Pelaia C; Lio E; Busceti MT; Pelle MC; Ricchio M; Scaglione V; Davoli C; Fusco P; La Gamba V; Torti C; Pelaia G
    Ther Adv Respir Dis; 2020; 14():1753466620963016. PubMed ID: 33070706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.
    Tremblay D; Seah C; Schneider T; Bhalla S; Feld J; Naymagon L; Wang B; Patel V; Jun T; Jandl T; Rahman F; Liu STH; Aberg JA; Bouvier N;
    Cancer Med; 2020 Nov; 9(22):8571-8578. PubMed ID: 32945149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
    Pavia CS; Wormser GP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
    Subbarao K; Mordant F; Rudraraju R
    Eur J Immunol; 2020 Oct; 50(10):1447-1453. PubMed ID: 32886952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Chronology of COVID-19 Pandemic.
    Siddiqui S; Alhamdi HWS; Alghamdi HA
    Front Public Health; 2022; 10():778037. PubMed ID: 35602161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.